中信证券股份有限公司 关于江西天新药业股份有限公司 2024 年度持续督导工作现场检查报告 根据《上海证券交易所上市公司自律监管指引第 11 号——持续督导》等有 关法律、法规的规定，中信证券股份有限公司（以下简称"中信证券"或"保荐 人"）作为正在对江西天新药业股份有限公司（以下简称"天新药业""公司" "上市公司"）进行持续督导工作的保荐人，对 2024 年度（以下简称"本持续督 导期间"）的规范运作情况进行了现场检查，现就现场检查的有关情况报告如下： 一、本次现场检查的基本情况 （一）保荐人 中信证券股份有限公司 （二）保荐代表人 丁元、庄林 （三）现场检查人员 丁元、康偌彤 （四）现场检查时间 （一）公司治理和内部控制情况 现场检查人员查阅了上市公司最新章程、三会议事规则及会议材料，财务管 理、会计核算、内部审计、募集资金管理以及关联交易、对外担保、对子公司的 控制等相关制度，查阅了公司 2024 年度内部控制评价报告、会计师内部控制审 计报告等文件，对高级管理人员进行访谈。 经查阅前述文件，保荐人认为： 2025 年 4 月 25 日、2025 年 4 月 28 日 （五）现场检查内容 现场检查人员 ...

中信证券股份有限公司 关于江西天新药业股份有限公司 2024年度持续督导报告书 | 上市公司：江西天新药业股份有限公司（以下简称"天新药业"、"公司"） | | | --- | --- | | 保荐人名称：中信证券股份有限公司（以下简称"中信证券"或"保荐人"） | | | 保荐代表人姓名：丁元 | 联系电话：021-20262071 | | 保荐代表人姓名：庄林 | 联系电话：021-20262071 | 经中国证券监督管理委员会《关于核准江西天新药业股份有限公司首次公开 发行股票的批复》（证监许可［2022］1220 号）核准，并经上海证券交易所同 意，公司于 2022 年 7 月 1 日首次向社会公开发行人民币普通股（A 股）4,378.00 万股，每股发行价格为 36.88 元，募集资金总额为 1,614,606,400.00 元，扣除各 类发行费用之后实际募集资金净额 1,517,233,100.00 元。中汇会计师事务所（特 殊普通合伙）于 2022 年 7 月 7 日对江西天新药业股份有限公司首次公开发行股 票的资金到位情况进行了审验，并出具了"中汇会验［2022］5910 号"验资报 告。20 ...

中信证券股份有限公司关于 江西天新药业股份有限公司首次公开发行股票并上市 持续督导保荐总结报告书 | 申报时间：2025 | | --- | | 年 5 月 | | 保荐人编号：Z20374000 | 1 导期至 2024 年 12 月 31 日止。2024 年 12 月 31 日，持续督导期已届满，中信证 券根据《证券发行上市保荐业务管理办法》（以下简称"《保荐办法》"）和相关规 定，出具本保荐总结报告书。 三、保荐工作概述 （一）尽职推荐阶段 按照法律、行政法规和中国证监会的规定，对公司及董事、监事、高级管理 人员进行尽职调查，组织编制申请文件并出具推荐文件；提交推荐文件后，主动 配合中国证监会的审核，组织公司及其他中介机构对中国证监会的意见进行答 复，按照中国证监会的要求对涉及本次证券发行上市的相关事项进行尽职调查或 者核查，并与中国证监会进行专业沟通；按照上海证券交易所上市规则的要求向 上海证券交易所提交推荐股票上市所要求的相关文件，并报中国证监会备案。 | 公司中文名称： | 江西天新药业股份有限公司 | | --- | --- | | 公司英文名称： | Jiangxi Tianxin Pharm ...

证券代码：603235 证券简称：天新药业 公告编号：2025-022 重要内容提示： 公司已分别于 2025 年 4 月 26 日、2025 年 4 月 30 日发布公司 2024 年年度 报告、2025 年第一季度报告，为便于广大投资者更全面深入地了解公司 2024 年 度及 2025 年第一季度的经营成果、财务状况，公司计划于 2025 年 5 月 13 日（星 期二）下午 15:00-16:00 举行 2024 年度暨 2025 年第一季度业绩说明会，就投资 者关心的问题进行交流。 一、说明会类型 本次业绩说明会以网络互动形式召开，公司将针对 2024 年度及 2025 年第一 会议召开时间：2025 年 5 月 13 日（星期二）下午 15:00-16:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 5 月 6 日（星期二）至 5 月 12 日（星期一）16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过江西 ...

Group 1: Market Overview - The three major stock indices experienced narrow fluctuations, with the North Stock 50 Index showing relative strength, while the Shanghai Composite Index fell by 0.05% to 3286.65 points, and the Shenzhen Component Index also dropped by 0.05% to 9849.8 points [1] - The total trading volume in the Shanghai, Shenzhen, and North Stock markets was 10,419 billion, a decrease of 350 billion from the previous day [1] - Sectors such as electricity and insurance declined, while home furnishings, automotive, chemicals, healthcare, agriculture, food and beverage, home appliances, and semiconductors saw gains [1] Group 2: Investment Opportunities in Smart Connected Vehicles - The Ministry of Industry and Information Technology (MIIT) has released key points for automotive standardization by 2025, emphasizing the need to strengthen standards for driving assistance and autonomous driving [2] - CITIC Securities anticipates that companies in the industry chain will focus on improving product maturity and safety, with main manufacturers expected to refine hardware and software architectures [2] - Investment recommendations include leading manufacturers in smart driving development, top suppliers of laser radar, and companies providing testing and simulation services for smart connected vehicles [2] Group 3: Smart Imaging Devices Market - The market for handheld smart imaging devices is projected to reach 36.47 billion in 2023, with a compound annual growth rate (CAGR) of approximately 12.9% from 2023 to 2027, potentially reaching 59.2 billion by 2027 [3] - The panoramic camera market is expected to reach 5 billion, with applications expanding beyond daily life and sports to include video conferencing and robotics [3] - The global market for action cameras is expected to exceed 30 billion in 2023, driven by the rise of outdoor sports [3] Group 4: Vitamin D3 Price Outlook - The price of feed-grade Vitamin D3 is at a historical low, leading to production cuts and supply reductions among some manufacturers [5] - Demand for Vitamin D3 is steadily increasing, with manufacturers reducing output since the beginning of 2024, resulting in historically low inventory levels [5] - Recent price increases have been observed, with significant adjustments in quotes from manufacturers, indicating potential for further price rises [5] Group 5: Consumption Policy and Tax Refunds - The National Taxation Administration has revised the management measures for tax refunds for outbound tourists, simplifying processes and expanding coverage to more small and medium-sized businesses [6] - CITIC Securities estimates that the potential market for tax refunds could reach nearly 100 billion, which may further stimulate consumption and expand domestic demand [6] - Key sectors to watch include traditional retail companies with strong operational capabilities and those involved in consumer infrastructure and travel services [6] Group 6: Electricity Market Developments - The National Development and Reform Commission and the National Energy Administration have announced plans to accelerate the construction of a national electricity spot market, aiming for full coverage by the end of 2025 [8] - Specific timelines have been set for the transition to formal operations in various provinces, with a focus on continuous settlement operations [8] Group 7: Digital Economy Infrastructure - The National Development and Reform Commission is promoting the construction of a national integrated computing network to optimize resource allocation and support the development of the digital economy [9] Group 8: Livestock Production Adjustments - The Ministry of Agriculture and Rural Affairs has issued a plan to adjust and optimize pig production capacity, focusing on monitoring and guiding the market [10]

证券代码：603235 证券简称：天新药业 登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假 记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息的真 实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一) 主要会计数据和财务指标 单位：元 币种：人民币 二、 股东信息 (一) 普通股股东总数和表决权恢复的优先股股东数量及前十名股东持股情况表 单位：股 注：公司回购专用账户未在"前10名股东持股情况"及"前10名无限售条件股东持股情况"中列示。截至 2025年3月31日，公司回购专用证券账户股份数量为2,609,720股。 (二) 非经常性损益项目和金额 √适用 □不适用 单位:元 币种:人民币 对公司将《公开发行证券的公司信息披露解释性公告第1号——非经常 ...

证券代码：603235 证券简称：天新药业 公告编号：2025-021 江西天新药业股份有限公司 关于 2025 年第一季度经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据上海证券交易所《上海证券交易所上市公司自律监管指引第 3 号——行 业信息披露》的相关规定，现将江西天新药业股份有限公司（以下简称"公司"） 2025 年第一季度经营数据（未经审计）公告如下： 一、 2025年第一季度主要经营数据 1、主营业务分产品情况 单位：元 币种：人民币 | 产品分类 | 2025 | 年 1-3 | 月收入 | 2024 | 年 1-3 月收入 | 同比变动 | | --- | --- | --- | --- | --- | --- | --- | | B 族维生素 | | 508,399,113.57 | | | 409,717,324.36 | 24.09% | | 其他维生素 | | 65,866,984.56 | | | 57,064,938.52 | 15.42% | | 精细化工品 | | 38,60 ...

Financial Performance - The company's operating revenue for Q1 2025 was CNY 618,910,665.47, representing a year-on-year increase of 25.16% compared to CNY 494,498,107.04 in the same period last year[4] - Net profit attributable to shareholders was CNY 218,567,101.74, up 48.13% from CNY 147,549,004.33 year-on-year[4] - Basic earnings per share rose to CNY 0.50, a 47.06% increase from CNY 0.34 in the same period last year[4] - The net profit excluding non-recurring gains and losses was CNY 208,976,403.83, marking a 53.30% increase from CNY 136,315,268.67 year-on-year[4] - The total profit for the period was CNY 259,915,720.06, compared to CNY 175,736,320.18 in the previous year, marking an increase of about 48%[20] - Operating profit for the period was CNY 259,904,968.64, up from CNY 176,366,401.91, reflecting a growth of approximately 47%[20] Cash Flow - The net cash flow from operating activities increased by 93.01%, reaching CNY 181,260,939.22, compared to CNY 93,913,720.58 in the previous year[4] - Cash flow from operating activities generated a net amount of CNY 181,260,939.22, compared to CNY 93,913,720.58 in the same quarter last year, indicating a year-over-year increase of 93%[24] - The company reported cash inflow from investment activities of CNY 1,291,300,379.67, a substantial increase from CNY 143,896,761.18 in Q1 2024[26] - Cash outflow from investment activities totaled CNY 1,006,366,733.99, compared to CNY 262,873,722.59 in the same quarter last year[26] - The company’s cash flow from financing activities generated a net amount of CNY 81,271,054.80, slightly down from CNY 90,747,637.45 in Q1 2024[26] Assets and Liabilities - Total assets at the end of the reporting period were CNY 5,814,847,133.34, reflecting a 3.78% increase from CNY 5,603,291,129.63 at the end of the previous year[5] - Total liabilities decreased to CNY 977,910,048.69 as of March 31, 2025, from CNY 987,405,152.49 at the end of 2024, a reduction of 0.5%[17] - Total current assets increased to ¥3,443,854,577.84 in the latest reporting period, compared to ¥3,331,373,369.70 previously, reflecting a growth of 3.4%[30] - The total liabilities decreased to ¥569,026,318.24 from ¥704,835,472.43, a reduction of approximately 19.2%[32] Shareholder Information - The top ten shareholders include Xu Jiangnan, holding 46.51% of shares, and Xu Jing, holding 13.50%[11] - The total equity attributable to shareholders increased to CNY 4,836,937,084.65 as of March 31, 2025, compared to CNY 4,615,885,977.14 at the end of 2024, marking a growth of 4.8%[18] Research and Development - Research and development expenses for Q1 2025 were CNY 20,722,319.47, a decrease of 9.1% from CNY 22,774,738.56 in Q1 2024[19] - Research and development expenses for Q1 2025 were ¥11,304,137.20, up from ¥9,686,583.82 in Q1 2024, indicating a focus on innovation[35] Non-Recurring Gains and Losses - The company reported a total of CNY 9,590,697.91 in non-recurring gains and losses for the period[6] - The company experienced a decrease in credit impairment losses, which improved from CNY -2,357,578.37 in Q1 2024 to CNY -780,792.60 in Q1 2025[20] Cash Position - Cash and cash equivalents as of March 31, 2025, totaled CNY 1,624,850,171.78, an increase of 50.8% from CNY 1,078,329,053.57 on December 31, 2024[14] - The ending balance of cash and cash equivalents reached ¥1,593,614,601.43, up from ¥2,309,350,155.08 at the end of the previous period[39]

Core Viewpoint - Jiangxi Tianxin Pharmaceutical Co., Ltd. reported a revenue of 2.209 billion yuan for 2024, a year-on-year increase of 17.35%, and a net profit of 651 million yuan, up 36.85% [1] Industry Recovery - The vitamin industry is experiencing a mild recovery due to demand resurgence and reduced competitive pressure, with overall market demand expected to grow due to population increase and rising health awareness [2] - China has become a major producer and exporter of vitamins, with domestic companies holding competitive advantages in production capabilities and costs [2] Company Performance - The revenue from B vitamins reached 1.731 billion yuan in 2024, reflecting a 4.9% year-on-year growth, with a gross margin of 49.61%, an increase of 7.7 percentage points [3] Competitive Advantage Development - Tianxin Pharmaceutical is enhancing its competitive edge through product diversification, technological advancements, and supply chain improvements, including the establishment of a production base in Ningxia [4] - The company plans to expand its product offerings with new products like vitamin B5 and vitamin A, aiming to strengthen its market position [4][5] Future Outlook - The vitamin prices are expected to remain stable or slightly increase in 2025, which may further enhance industry profitability [6] - The growing consumer demand for health foods, particularly for B vitamins as nutritional enhancers, is anticipated to drive market demand [6]

登录新浪财经APP 搜索【信披】查看更多考评等级 2025年4月25日，公司召开第三届董事会第九次会议和第三届监事会第八次会议，审议通过了《关于使 用闲置募集资金进行现金管理的议案》，公司及子公司拟使用最高额度不超过人民币2亿元的闲置募集 资金进行现金管理，适时向各金融机构购买安全性高、流动性好的保本型产品（包括但不限于结构性存 款、定期存款、通知存款、大额存单、协定存款等）。在确保不影响募集资金投资项目建设和募集资金 使用的前提下，资金可以在十二个月内滚动使用。 一、使用闲置募集资金进行现金管理的基本情况 （一）投资目的 为充分发挥募集资金使用效率、适当增加收益，在确保不影响公司正常经营、不影响募集资金项目建设 和募集资金使用计划的前提下，公司及子公司使用部分暂时闲置募集资金进行现金管理。 （二）投资金额 本次进行现金管理的资金来源为公司及子公司闲置募集资金，额度为不超过人民币2亿元。在上述额度 内，公司可以循环滚动使用。 （三）资金来源及相关情况 本次进行现金管理的资金来源为公司及子公司闲置募集资金。 经中国证券监督管理委员会《关于核准江西天新药业股份有限公司首次公开发行股票的批复》（证监许 可[2022 ...